Actively Recruiting
Comparing the Safety and Immune Response of Adjuvanted and Non-Adjuvanted Influenza Vaccines in Elderly Adults with Chronic Conditions
Led by National Taiwan University Hospital · Updated on 2026-02-24
200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the immune response, safety, and overall effects of two types of seasonal influenza vaccines in elderly Taiwanese people with chronic health conditions. The study compares an adjuvanted influenza vaccine aIIV4 with a non-adjuvanted influenza vaccine IIV4. This research aims to provide local data on vaccine safety and effectiveness, as current evidence suggests adjuvanted vaccines may better protect older adults who often have weakened immune responses. Participants will be randomly assigned to receive either the adjuvanted or non-adjuvanted vaccine. The study lasts one year and monitors immune responses and safety after vaccination. Key focus is on measuring antibody changes 29 days post-vaccination and following participants up to 361 days to assess immune protection, adverse reactions, and flu infection rates. During the study, participants will have blood samples taken before vaccination, around Day 29, and at Days 181 and 361 to evaluate immune responses. Researchers will track any severe side effects within 28 days after vaccination and monitor flu-related emergency visits, hospitalizations, and overall health during the year. The main measure is the rate at which participants develop protective antibodies by Day 29.
CONDITIONS
Brief Title
Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines
Research Team
J
Jann-Tay Wang Clinical Professor, M. D., Ph.D.
U
Un-In Wu Clinical Associate Professor, M. D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here